{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:23:17Z","timestamp":1776748997410,"version":"3.51.2"},"reference-count":37,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ersjournals.com"],"crossmark-restriction":true},"short-container-title":["Breathe"],"accepted":{"date-parts":[[2020,4,16]]},"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:p><jats:bold>Educational aims<\/jats:bold><\/jats:p><jats:p>This article is mainly intended for trainees and specialists who are interested in the management of severe asthma.<jats:list list-type=\"bullet\"><jats:list-item><jats:p>It aims to inform readers about the updated ERS\/ATS recommendations for management of severe asthma, specifically on the topics of biologics, macrolides and long-acting muscarinic antagonists.<\/jats:p><\/jats:list-item><jats:list-item><jats:p>It also provides guidance on utilisation of available biomarkers in selecting advanced therapies in severe asthma.<\/jats:p><\/jats:list-item><\/jats:list><\/jats:p>","DOI":"10.1183\/20734735.0058-2020","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:40:14Z","timestamp":1601041214000},"page":"200058","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Management of severe asthma: summary of the European Respiratory Society\/American Thoracic Society task force report"],"prefix":"10.1183","volume":"16","author":[{"given":"Sandhya","family":"Khurana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Bush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0979-8234","authenticated-orcid":false,"given":"Fernando","family":"Holguin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"2024101703504911000_16.2.200058.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200906-0896OC"},{"key":"2024101703504911000_16.2.200058.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200711-1754OC"},{"key":"2024101703504911000_16.2.200058.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00779-2015"},{"key":"2024101703504911000_16.2.200058.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.11.015"},{"key":"2024101703504911000_16.2.200058.5","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2024101703504911000_16.2.200058.6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00588-2019"},{"key":"2024101703504911000_16.2.200058.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2024101703504911000_16.2.200058.8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024101703504911000_16.2.200058.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"2024101703504911000_16.2.200058.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.03.032"},{"key":"2024101703504911000_16.2.200058.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201103-0396OC"},{"key":"2024101703504911000_16.2.200058.12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2024101703504911000_16.2.200058.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.03.018"},{"key":"2024101703504911000_16.2.200058.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"2024101703504911000_16.2.200058.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"2024101703504911000_16.2.200058.16","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"2024101703504911000_16.2.200058.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30307-5"},{"key":"2024101703504911000_16.2.200058.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"2024101703504911000_16.2.200058.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"2024101703504911000_16.2.200058.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.04.039"},{"key":"2024101703504911000_16.2.200058.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208606"},{"key":"2024101703504911000_16.2.200058.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01100-2016"},{"key":"2024101703504911000_16.2.200058.23","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2017.01.014","article-title":"A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma","volume":"140","author":"Szefler","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2024101703504911000_16.2.200058.24","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202698"},{"key":"2024101703504911000_16.2.200058.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31281-3"},{"key":"2024101703504911000_16.2.200058.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.09.028"},{"key":"2024101703504911000_16.2.200058.27","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2012.04.110309"},{"key":"2024101703504911000_16.2.200058.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.07.024"},{"key":"2024101703504911000_16.2.200058.29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200707-1134OC"},{"key":"2024101703504911000_16.2.200058.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106469"},{"key":"2024101703504911000_16.2.200058.31","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2024101703504911000_16.2.200058.32","doi-asserted-by":"publisher","DOI":"10.1159\/000444799"},{"key":"2024101703504911000_16.2.200058.33","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024101703504911000_16.2.200058.34","doi-asserted-by":"crossref","unstructured":"Normansell R , Walker S , Milan SJ , et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; CD003559.","DOI":"10.1002\/14651858.CD003559.pub4"},{"key":"2024101703504911000_16.2.200058.35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2024101703504911000_16.2.200058.36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaci.2013.02.032","article-title":"High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects","volume":"132","author":"Busse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2024101703504911000_16.2.200058.37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201208-1414OC"}],"container-title":["Breathe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/20734735.0058-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:30:50Z","timestamp":1729164650000},"score":1,"resource":{"primary":{"URL":"http:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/20734735.0058-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,9,25]]},"published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1183\/20734735.0058-2020"],"URL":"https:\/\/doi.org\/10.1183\/20734735.0058-2020","relation":{},"ISSN":["1810-6838","2073-4735"],"issn-type":[{"value":"1810-6838","type":"print"},{"value":"2073-4735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}